Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 16 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR AlterationsRecruitingNCT05560334Phase 2
• Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyNot yet recruitingNCT05560308Not applicable
• A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard TherapyRecruitingNCT05559775Phase 2
• Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)RecruitingNCT05559645Not applicable
• A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
• A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsRecruitingNCT05556200Phase 2
• The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal CancerRecruitingNCT05555901Phase 2
• To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR MutationRecruitingNCT05555212Phase 1
• H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLCRecruitingNCT05552781Phase 1/2
• Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial CancerNot yet recruitingNCT05550558Phase 2
• Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCRecruitingNCT05549466Phase 2
• First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon MutationRecruitingNCT05548348Phase 2
• To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET DysregulationRecruitingNCT05541822Phase 2
• Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable MelanomaNot yet recruitingNCT05539118Phase 1/2
• Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)RecruitingNCT05536349Phase 2
• Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCCRecruitingNCT05533892Phase 1
• Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC PatientsRecruitingNCT05532696Phase 1/2
• Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced CholangiocarcinomaRecruitingNCT05532059Phase 2
• Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)RecruitingNCT05531786Phase 1/2
• Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
• Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaRecruitingNCT05528458Phase 2
• Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid TumorsNot yet recruitingNCT05527821Phase 2
• Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib BloodlevelsRecruitingNCT05525338Phase 4
• Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different GenotypesNot yet recruitingNCT05524974Phase 2
• Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal CancerRecruitingNCT05522738Phase 1/2
• FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT05522309Phase 1
• Olverembatinib for FGFR1-rearranged NeoplasmsRecruitingNCT05521204Phase 2
• Study to Evaluate the Efficacy of Afatinib in Skull Base ChordomaNot yet recruitingNCT05519917Phase 2
• Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2
• Phase I/IIa Study of H002 in NSCLC With Active EGFR MutationRecruitingNCT05519293Phase 1/2
• A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete ResectionNot yet recruitingNCT05514314Phase 2
• Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaRecruitingNCT05504603Phase 2
• Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisNot yet recruitingNCT05502731Phase 4
• A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid TumorRecruitingNCT05498519Phase 1
• Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
• XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingNCT05494060Phase 2
• Imatinib TDM in GISTRecruitingNCT05493215Phase 2
• Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic LymphohistiocytosisRecruitingNCT05491304Phase 4
• A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to IbrutinibRecruitingNCT05491044Phase 2
• Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid TumorRecruitingNCT05490667Not applicable
• A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerRecruitingNCT05482568Phase 1/2
• A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLCNot yet recruitingNCT05482087Phase 2
• Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT05479487Phase 2
• Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 2
• Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsRecruitingNCT05468359Phase 1/2
• Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal CancerRecruitingNCT05462613Phase 2/3
• Baricitinib for Reduction of HIV - CNSRecruitingNCT05452564Phase 2
• Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line ChemotherapyNot yet recruitingNCT05451719Phase 2
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingNCT05447702Phase 2
• Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung CancerRecruitingNCT05445310Phase 2
• SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT05445154Phase 1/2
• Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular CarcinomaRecruitingNCT05444478Not applicable
• A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered MalignanciesRecruitingNCT05443126Phase 1/2
• A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC PatientsEnrolling by invitationNCT05441475Phase 2
• Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ CarcinomaRecruitingNCT05439993Phase 1/2
• Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung CancerRecruitingNCT05435274Phase 1/2
• Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)RecruitingNCT05435248Phase 1/2
• Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
• The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
• Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer PatientsNot yet recruitingNCT05426811Phase 1/2
• Cabozantinib for Patients With Recurrent or Progressive MeningiomaRecruitingNCT05425004Phase 2
• mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCRecruitingNCT05412589Phase 2
• Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)RecruitingNCT05410197Phase 2
• the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaRecruitingNCT05408221Phase 2/3
• A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionRecruitingNCT05407519Phase 2
• Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerRecruitingNCT05401110Phase 1
• Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingNCT05398809Phase 2
• A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLCRecruitingNCT05394831Phase 1/2
• BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT05393466Phase 1/2
• Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
• Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual DiseaseRecruitingNCT05388149Phase 2
• 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskRecruitingNCT05385549Phase 2
• A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)RecruitingNCT05384626Phase 1/2
• Axitinib and Nivolumab for the Treatment of Mucosal MelanomaRecruitingNCT05384496Phase 2
• Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA TrialRecruitingNCT05382741Phase 2
• Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)RecruitingNCT05382728Phase 3
• Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingNCT05381506Phase 2
• High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) MetastasesRecruitingNCT05379803Phase 2
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingNCT05372614Phase 1
• Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune ThrombocytopeniaNot yet recruitingNCT05369377Phase 2
• The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune ThrombocytopeniaNot yet recruitingNCT05369364Phase 2
• A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruitingNCT05367765Phase 4
• A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.RecruitingNCT05367700Phase 1
• A Study of ICP-033 in Patients With Advanced Solid TumorsRecruitingNCT05367232Phase 1
• ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingNCT05366816Phase 2
• Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More TreatmentRecruitingNCT05363280Phase 2
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2
• A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT05353205Phase 4
• Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
• WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLCRecruitingNCT05351320Phase 2
• Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
• Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyRecruitingNCT05342194Phase 3
• Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingNCT05341583Phase 3
• A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyRecruitingNCT05338619Phase 2
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
• Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System LymphomaRecruitingNCT05334238Phase 3
• Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell CancerNot yet recruitingNCT05322499Phase 2
• Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationRecruitingNCT05315700Phase 1/2
• Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingNCT05313958Phase 2/3
• Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2

← Tyrosine Kinase Inhibitors overview